Literature DB >> 23715012

Tracking of second primary melanomas in vemurafenib-treated patients.

Stephane Dalle, Nicolas Poulalhon, Sébastien Debarbieux, Daniela Zaharia, Martin C Mihm, Mario E Lacouture, Alyx Rosen, Ashfaq A Marghoob, Klaus J Busam, Lauriane Depaepe, Pierre-Paul Bringuier, Pauline Richez, Jean-François Baurain, Brigitte Bressac-de Paillerets, Brigitte Balme, Luc Thomas.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23715012     DOI： 10.1001/jamadermatol.2013.21

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN： 2168-6068            Impact factor:   10.282


× No keyword cloud information.
  7 in total

1.  Vemurafenib and cutaneous adverse events--report of five cases.

Authors:  Giselle de Barros Silva; Adriana Pessoa Mendes; Mariana Petaccia de Macedo; Clóvis Antônio Lopes Pinto; Ivana Lameiras Gibbons; João Pedreira Duprat Neto
Journal:  An Bras Dermatol       Date:  2015 May-Jun       Impact factor: 1.896

Review 2.  Cutaneous toxicities of new treatments for melanoma.

Authors:  A Boada; C Carrera; S Segura; H Collgros; P Pasquali; D Bodet; S Puig; J Malvehy
Journal:  Clin Transl Oncol       Date:  2018-05-24       Impact factor: 3.405

Review 3.  Managing the skin toxicities from new melanoma drugs.

Authors:  John C Mavropoulos; Timothy S Wang
Journal:  Curr Treat Options Oncol       Date:  2014-06

4.  NRAS Q61R and BRAF G466A mutations in atypical melanocytic lesions newly arising in advanced melanoma patients treated with vemurafenib.

Authors:  Vishwas Parekh; Joseph Sobanko; Christopher J Miller; Giorgos Karakousis; Wei Xu; Richard Letrero; Rosalie Elenitsas; Xiaowei Xu; David E Elder; Ravi Amaravadi; Lynn M Schuchter; Katherine L Nathanson; Melissa A Wilson; Emily Y Chu
Journal:  J Cutan Pathol       Date:  2018-12-27       Impact factor: 1.587

Review 5.  BRAF inhibitors: experience in thyroid cancer and general review of toxicity.

Authors:  M E Cabanillas; A Patel; B P Danysh; R Dadu; S Kopetz; G Falchook
Journal:  Horm Cancer       Date:  2014-12-03       Impact factor: 3.869

6.  Melanoma patients under vemurafenib: prospective follow-up of melanocytic lesions by digital dermoscopy.

Authors:  Marie Perier-Muzet; Luc Thomas; Nicolas Poulalhon; Sébastien Debarbieux; Pierre-Paul Bringuier; Gerard Duru; Lauriane Depaepe; Brigitte Balme; Stephane Dalle
Journal:  J Invest Dermatol       Date:  2013-11-07       Impact factor: 8.551

7.  BRAFV600E induces reversible mitotic arrest in human melanocytes via microrna-mediated suppression of AURKB.

Authors:  Andrew S McNeal; Rachel L Belote; Hanlin Zeng; Marcus Urquijo; Kendra Barker; Rodrigo Torres; Meghan Curtin; A Hunter Shain; Robert Hi Andtbacka; Sheri Holmen; David H Lum; Timothy H McCalmont; Matt W VanBrocklin; Douglas Grossman; Maria L Wei; Ursula E Lang; Robert L Judson-Torres
Journal:  Elife       Date:  2021-11-23       Impact factor: 8.140
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.